Gyre Therapeutics Inc. highlighted its leadership in the treatment of idiopathic pulmonary fibrosis (IPF) in China, with its product ETUARY® (pirfenidone) maintaining the largest market share for ten consecutive years. The company reported that over 150,000 IPF patients have been treated with pirfenidone across more than 3,000 hospitals and pharmacies in 870+ cities in China. Recent strategic moves include the acquisition of generic Etorel (nintedanib) to expand IPF treatment options, and the addition of Contiva (avatrombopag) to establish a presence in the liver disease market, in preparation for the future launch of Hydronidone. Gyre Therapeutics also announced positive Phase 3 results for Hydronidone in chronic hepatitis B-associated liver fibrosis, with statistically significant improvements in fibrosis regression and inflammation. The safety profile showed a low rate of serious adverse events and no discontinuations due to adverse events. The company continues to advance its clinical pipeline in other chronic organ diseases, including pulmonary arterial hypertension and COPD. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief on January 27, 2026, and is solely responsible for the information contained therein.